MediPharm Labs (MediPharm Labs) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Debt-to-Equity?

MediPharm Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.52 Mil. MediPharm Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.04 Mil. MediPharm Labs's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $36.83 Mil. MediPharm Labs's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MediPharm Labs's Debt-to-Equity or its related term are showing as below:

MEDIF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 0.3
Current: 0.04

During the past 7 years, the highest Debt-to-Equity Ratio of MediPharm Labs was 0.30. The lowest was 0.00. And the median was 0.05.

MEDIF's Debt-to-Equity is ranked better than
84.06% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs MEDIF: 0.04

MediPharm Labs Debt-to-Equity Historical Data

The historical data trend for MediPharm Labs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Debt-to-Equity Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.24

0.01

0.04

MediPharm Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	0.05	0.05	0.04	0.04

Competitive Comparison of MediPharm Labs's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediPharm Labs's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Debt-to-Equity falls into.

MediPharm Labs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MediPharm Labs's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.659	+	0.051)	/	39.509
	=	0.04

MediPharm Labs's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.52	+	0.043)	/	36.831
	=	0.04

MediPharm Labs (OTCPK:MEDIF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MediPharm Labs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs (MediPharm Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (OTCPK:MEDIF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MLZ:Germany LABS:Canada

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.